Publication | Closed Access

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

ObesityMetabolic SyndromeWithout Type 2MedicineMultiple-dose AdministrationDiabetesPharmacotherapyDiabetes MellitusInsulin DeliveryPharmacology